company background image
BHN0 logo

BELLUS Health DB:BHN0 Stock Report

Last Price

€13.40

Market Cap

€1.7b

7D

0.8%

1Y

43.2%

Updated

29 Jun, 2023

Data

Company Financials +

This company is no longer active

The company may no longer be operating, as it may be out of business. Find out why through their latest events.

BHN0 Stock Overview

BELLUS Health Inc., a clinical-stage biopharmaceutical company, develops therapeutics for the treatment of refractory chronic cough (RCC) and other cough hypersensitivity indications. More details

BHN0 fundamental analysis
Snowflake Score
Valuation0/6
Future Growth2/6
Past Performance0/6
Financial Health6/6
Dividends0/6

My Notes

Capture your thoughts, links and company narrative

BELLUS Health Inc. Competitors

Price History & Performance

Summary of share price highs, lows and changes for BELLUS Health
Historical stock prices
Current Share PriceCA$13.40
52 Week HighCA$13.60
52 Week LowCA$5.85
Beta-0.28
1 Month Change-0.74%
3 Month Change104.42%
1 Year Change43.16%
3 Year Change34.67%
5 Year Change1,132.53%
Change since IPO-72.33%

Recent News & Updates

Recent updates

Shareholder Returns

BHN0DE BiotechsDE Market
7D0.8%-2.6%-2.0%
1Y43.2%-13.2%6.8%

Return vs Industry: BHN0 exceeded the German Biotechs industry which returned -5.6% over the past year.

Return vs Market: BHN0 exceeded the German Market which returned 4.2% over the past year.

Price Volatility

Is BHN0's price volatile compared to industry and market?
BHN0 volatility
BHN0 Average Weekly Movement30.8%
Biotechs Industry Average Movement6.9%
Market Average Movement4.9%
10% most volatile stocks in DE Market11.4%
10% least volatile stocks in DE Market2.4%

Stable Share Price: BHN0's share price has been volatile over the past 3 months.

Volatility Over Time: BHN0's weekly volatility has increased from 16% to 31% over the past year.

About the Company

FoundedEmployeesCEOWebsite
199374Roberto Belliniwww.bellushealth.com

BELLUS Health Inc., a clinical-stage biopharmaceutical company, develops therapeutics for the treatment of refractory chronic cough (RCC) and other cough hypersensitivity indications. Its lead product candidate includes BLU-5937, an antagonist of the P2X3 receptor, which is in Phase II clinical trial for treatment of RCC and chronic pruritus. BELLUS Health Inc. was incorporated in 1993 and is based in Laval, Canada.

BELLUS Health Inc. Fundamentals Summary

How do BELLUS Health's earnings and revenue compare to its market cap?
BHN0 fundamental statistics
Market cap€1.71b
Earnings (TTM)-€79.52m
Revenue (TTM)€13.74k

Over9,999x

P/S Ratio

-21.5x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
BHN0 income statement (TTM)
RevenueUS$15.00k
Cost of RevenueUS$0
Gross ProfitUS$15.00k
Other ExpensesUS$86.80m
Earnings-US$86.79m

Last Reported Earnings

Mar 31, 2023

Next Earnings Date

n/a

Earnings per share (EPS)-0.68
Gross Margin100.00%
Net Profit Margin-578,586.67%
Debt/Equity Ratio0%

How did BHN0 perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2023/06/29 18:30
End of Day Share Price 2023/06/28 00:00
Earnings2023/03/31
Annual Earnings2022/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

BELLUS Health Inc. is covered by 12 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Brian SkorneyBaird
Justin ZelinBTIG
Pooya HemamiEdison Investment Research